Autolus Therapeutics (AUTL) Stock Highlights

2.29 | +2.23%

2024-12-21 04:36:10

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer. The companys clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Statistics

Range Today

2.2 2.35

Volume Today 2.61M

Range 1 Year

2.24 7.45

Volume 1 Year 377.32M

Range 3 Year

1.6 7.45

Volume 3 Year 609.39M

Range 10 Year

1.6 53.24

Volume 10 Year 994.39M

Highlights

Market Capitalization 992.53M (small)

Floating Shares 131.58M

Current Price 2.29

Price To Earnings -3.54

Price To Revenue 54.8

Price To Book 1.88

Earnings Per Share -1.14

Payout Ratio 0%

Performance

Latest +2.23%

1 Month -22.9%

3 Months -40.05%

6 Months -42.17%

1 Year -55.96%

3 Years -56.79%

5 Years -82.64%

10 Years -91.82%

Benchmarks

Market Capitalization

102 / 368

Gross Profits

248 / 278

Total Revenue

200 / 300

Total Rank

200 / 368

Free Cashflow

298 / 352

Performance 5 years

240 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.